Search clinical trials for: Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (F

Total 136 results

MRC [ycm]

Completed

Pre-exposure Option for Reducing HIV in the UK.(PROUD) (PROUD)

HIV

United Kingdom
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
ANRS, Emerging Infectious Diseases
Gilead Sciences; Ministry of Health, Thailand; Assistance Publique - Hôpitaux... and other collaborators

Not yet recruiting

Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. (SimpPrEP)

HIV/AIDS

France, Thailand
University of California, San Diego

Active, not recruiting

Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis (TAF4TRANS)

Hiv | Hormone Therapy

United States
Yonsei University

Unknown

HIV Pre-exposure Prophylaxis Implementation Study in South Korea

HIV Infections

Korea, Republic of
University of KwaZulu
Medical Research Council, South Africa; Centre for the AIDS Programme of Research...

Completed

Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women (PrEP)

HIV-1-infection

South Africa
Kirby Institute

Completed

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

HIV Infections

Australia
Professor Francois Venter

Completed

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (ADVANCE)

HIV-1 Infection

South Africa
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

HIV Infections

Zimbabwe, Uganda
Rhonda Brand
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs (APTAMER)

HIV | Medication Adherence

United States
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women

HIV Infections

South Africa, Uganda, Zimbabwe
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection (DISCOVER)

Pre-Exposure Prophylaxis of HIV-1 Infection

United States, Austria, Denmark, United Kingdom, Netherlands, Italy, Germany, Canada, Ireland, France, Spain
Desmond Tutu HIV Centre
National Institute of Mental Health (NIMH); Bill and Melinda Gates Foundation; University of Washington

Unknown

3Ps for Prevention Study (Perception, Partners, Pills) (3P)

Adherence

South Africa
University of California, Los Angeles
Los Angeles County Department of Public Health; Los Angeles LGBT Center; The... and other collaborators

Completed

A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services (PATH-PrEP)

HIV Prevention

United States
University of Washington
Bill and Melinda Gates Foundation

Completed

Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples (Partners PrEP)

HIV Infections | HIV-1 Infections

Kenya, Uganda
The University of Texas Health Science Center,...
Merck Sharp & Dohme LLC; Gilead Sciences

Completed

Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)

HIV

United States
Gilead Sciences

Completed

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

Chronic Hepatitis B

United States, Canada, Spain, Singapore, Turkey, Germany, France, Taiwan, Greece, Italy, Poland
Gilead Sciences
HIV Prevention Trials Network

Recruiting

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN-102) (PURPOSE 3)

Pre-Exposure Prophylaxis of HIV Infection

United States
Gilead Sciences

Active, not recruiting

Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection (PURPOSE 1)

Pre-Exposure Prophylaxis of HIV Infection

South Africa, Uganda
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

HIV Infection

United States
Columbia University
Research Foundation for Mental Hygiene, Inc.; Impact Research & Development...

Not yet recruiting

IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya

HIV
University of North Carolina, Chapel Hill
Bristol-Myers Squibb; Gilead Sciences

Completed

Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)

HIV Infections | Acute HIV Infection

United States
Gilead Sciences
National Institute on Drug Abuse (NIDA); National Institute of Allergy and... and other collaborators

Recruiting

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN-103) (PURPOSE-4)

Pre-Exposure Prophylaxis of HIV Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

HIV-1 Infection

Russian Federation, United States, Thailand, Uganda, Puerto Rico, Dominican Republic
Merck Sharp & Dohme LLC

Completed

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024) (Impower-024)

HIV Preexposure Prophylaxis

United States, Brazil, France, Japan, South Africa, Thailand, Peru
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

HIV/AIDS

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) (Impower-022)

Prophylaxis | Human Immunodeficiency Virus Type 1 | HIV-I

United States, South Africa, Uganda
Gilead Sciences

Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women (WAVES)

HIV Infections | Acquired Immunodeficiency Syndrome

United States, Thailand, France, Uganda, United Kingdom, Belgium, Portugal, Mexico, Dominican Republic, Italy, Puerto Rico, Russian Federation
Gilead Sciences

Completed

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults (Alliance)

HIV-1/HBV Co-Infection

Spain, Taiwan, Korea, Republic of, Thailand, Hong Kong, Japan, France, Turkey, Puerto Rico, Malaysia, United States, China, Dominican Republic, Greece
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs

HIV Infections

South Africa, Uganda, Malawi, Zimbabwe
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy

HIV Infections

South Africa, Uganda, Malawi, Zimbabwe
CHU de Quebec-Universite Laval
Johns Hopkins University; Gilead Sciences; Imperial College London; Bill and Melinda... and other collaborators

Completed

Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin (TasP/PrEP)

Adherence to Medication Regime

Benin
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

HIV Infections
Kenneth H. Mayer, MD
Gilead Sciences

Completed

HIV Non-Occupational Post-Exposure Prophylaxis (QUAD)

Human Immunodeficiency Virus

United States
British Columbia Centre for Disease Control

Unknown

Tenofovir/Emtricitabine With Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative MSM (DuDHS)

HIV | Syphilis

Canada
Johns Hopkins University

Withdrawn

Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)

Pregnancy | HIV-1-infection
Kirby Institute

Completed

PrEP Demonstration Project (PRELUDE Study) (PRELUDE)

HIV

Australia
University of Washington
University of Colorado, Denver; National Institute of Allergy and Infectious... and other collaborators

Active, not recruiting

The Women TDF-FTC Benchmark Study

HIV Infections

Kenya
FHI 360

Completed

FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women

HIV Infections

Kenya, South Africa, Tanzania
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents

HIV Infections

South Africa
Gilead Sciences

Completed

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

HIV Infections | HIV

Canada, United States, Spain, Puerto Rico, France, Switzerland, Australia, Germany, United Kingdom, Sweden, Brazil, Austria, Thailand, Netherlands, Belgium, Dominican Republic, Portugal, Italy, Denmark, Mexico
ANRS, Emerging Infectious Diseases

Recruiting

Prevention of HIV in "Île-de-France" (ANRS-PREVENIR)

HIV Infections

France
Eastern Virginia Medical School
Gilead Sciences; United States Agency for International Development (USAID); FHI... and other collaborators

Active, not recruiting

Project Engage: Oral PrEP Acceptability

Adherence, Medication | Acceptability of Health Care

South Africa, Zimbabwe
Thai Red Cross AIDS Research Centre

Recruiting

Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men

Drug Interaction

Thailand
Gilead Sciences

Completed

Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Gilead Sciences

Completed

Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum

HIV Infections

Malawi, Zimbabwe, South Africa, Uganda
Philadelphia Fight

Completed

PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color

HIV

United States
Massachusetts General Hospital
Solving MS

Enrolling by invitation

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

Multiple Sclerosis

United States

Search clinical trials for: Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (F

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations